高伟,顾红,胡大一,华益民,黄奕高,李奋,秦永文,宋治远,王广义,吴炳祥,徐仲英,徐卓明,张端珍,张伟华,张玉顺,周达新,朱鲜阳

• 1:中国医师协会心血管内科医师分会
• 2:上海儿童医学中心
• 3:首都医科大学附属北京安贞医院
• 4:北京大学人民医院

摘要(Abstract)：

<正>先天性心脏病(congenital heart disease,CHD)是我国引起肺动脉高压(pulmonary arterial hypertension,PAH)最常见的原因之一,诸多患者因PAH而失去手术机会。然而,CHD相关性PAH(PAH associated with CHD,PAH-CHD)如何诊治,目前尚无统一标准。为使患者获得最佳治疗方案,特撰写此共识,以期为PAH-CHD规范化诊治提供借鉴。1 PAH-CHD的定义

关键词(KeyWords)： 先天性心脏病;肺动脉高压共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 高伟,顾红,胡大一,华益民,黄奕高,李奋,秦永文,宋治远,王广义,吴炳祥,徐仲英,徐卓明,张端珍,张伟华,张玉顺,周达新,朱鲜阳

参考文献(References)：

• [1]Galie N,Manes A,Palazzini M,et al.Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.Drugs,2008,68:1049-1066.
• [2]Duffels MG,Engelfriet PM,Berger RM,et al.Pulmonary arterial hypertension in congenital heart disease:an epidemiologic perspective from a Dutch registry.Int J Cardiol,2007,120:198-204.
• [3]Diller GP,Gatzoulis MA.Pulmonary vascular disease in adults with congenital heart disease.Circulation,2007,115:1039-1050.
• [4]兰贝蒂,张玉顺.肺动脉高压合并小缺损先天性心脏病的认识与研究进展.心血管病学进展,2010,31:751-753.
• [5]丁仲如,秦永文.先天性心脏病合并肺动脉高压分级及性质的评估.介入放射学杂志,2008,17:523-526.
• [6]Baumgartner H,Bonhoeffer P,De Groot NM,et al.ESC Guidelines for the management of grown-up congenital heart disease(new version 2010).Eur Heart J,2010,31:2915-2957.
• [7]Diller GP,Dimopoulos K,Kafka H,et al.Model of chronic adaptation:right ventricular function in Eisenmenger syndrome.Eur Heart J,2007,9:54-60.
• [8]Daliento L,Somerville J,Presbitero P,et al.Eisenmenger syndrome.Factors relating to deterioration and death.Eur Heart J,1998,19:1845-1855.
• [9]Forfia PR,Fisher MR,Mathai SC,et al.Tricuspid annular displacement predicts survival in pulmonary hypertension.Am J Respir Crit Care Med,2006,174:1034-1041.
• [10]Inaba T,Yao A,Nakao T,et al.Volumetric and functional assessment of ventricles in pulmonary hypertension on 3-dimensional echocardiography.Circ J,2012,77:198-206.
• [11]Krichenko A,Benson LN,Burrows P,et al.Angiographic classification of the isolated,persistently patent ductus arteriosus and implications for percutaneous catheter occlusion.Am J Cardiol,1989,63:877-880.
• [12]Van Wolferen SA,Marcus JT,Boonstra A,et al.Prognostic value of right ventricular mass,volume,and function in idiopathic pulmonary arterial hypertension.Eur Heart J,2007,28:1250-1257.
• [13]Mc Laughlin VV,Archer SL,Badesch DB,et al.ACCF/AHA2009 expert consensus document on pulmonary hypertension:a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association:developed in collaboration with the American College of Chest Physicians,American Thoracic Society,Inc.,and the Pulmonary Hypertension Association.Circulation,2009,119:2250-2294.
• [14]Zhang DZ,Zhu XY,Meng J,et al.Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension.Int J Cardiol,2011,147:433-437.
• [15]张端珍,朱鲜阳,崔春生,等.先天性心脏病重度肺动脉高压对腺苷的急性反应.心脏杂志,2011,23:241-244.
• [16]Montani D,Savale L,Natali D,et al.Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.Eur Heart J,2010,31:1898-1907.
• [17]Limsuwan A,Khosithseth A,Wanichkul S,et al.Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease.Catheter Cardiovasc Interv,2009,73:98-104.
• [18]Lopes AA,O'Leary PW.Measurement,interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease.Cardiol Young,2009,19:431-435.
• [19]Nishimura T,Faul JL,Berry GJ,et al.Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.Am J Respir Crit Care Med,2002,166:1403-1408.
• [20]Girgis RE,Li D,Zhan X,et al.Attenuation of chronic hypoxic pulmonary hypertension by simvastatin.Am J Physiol Heart Circ Physiol,2003,285:938-945.
• [21]Kao PN.Simvastatin treatment of pulmonary hypertension:an observational case series.Chest,2005,127:1446-1452.
• [22]Mc Laughlin VV,Shillington A,Rich S.Survival in primary pulmonary hypertension:the impact of epoprostenol therapy.Circulation,2002,106:1477-1482.
• [23]Buckley MS,Feldman JP.Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.Pharmacotherapy,2010,30:728-740.
• [24]Rosenzweig EB,Kerstein D,Barst RJ.Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.Circulation,1999,99:1858-1865.
• [25]Fernandes SM,Newburger JW,Lang P,et al.Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology.Am J Cardiol,2003,91:632-635.
• [26]Thomas IC,Glassner-Kolmin C,Gomberg-Maitland M.Longterm effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.Int J Cardiol,2013,168:4117-4121.
• [27]Mc Intyre CM,Hanna BD,Rintoul N,et al.Safety of epoprostenol and treprostinil in children less than 12 months of age.Pulm Circ,2013,3:862-869.
• [28]Benza RL,Seeger W,Mc Laughlin VV,et al.Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension:the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension(TRIUMPH)study open-label extension.J Heart Lung Transplant,2011,30:1327-1333.
• [29]Sadushi-Kolici R,Skoro-Sajer N,Zimmer D,et al.Long-term treatment,tolerability,and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.J Heart Lung Transplant,2012,31:735-743.
• [30]Hill NS,Badesch D,Benza RL,et al.Perspectives on oral pulmonary hypertension therapies recently approved by the food and drug administration.Ann Am Thorac Soc,2015.[Epub ahead of print]
• [31]Olschewski H,Hoeper MM,Behr J,et al.Long-term therapy with inhaled iloprost in patients with pulmonary hypertension.Respir Med,2010,104:731-740.
• [32]Yang SI,Chung WJ,Jung SH,et al.Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome.Pediatr Cardiol,2012,33:744-748.
• [33]Cha KS,Cho KI,Seo JS,et al.Effects of inhaled iloprost on exercise capacity,quality of life,and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease(the Eisenmenger syndrome)(from the EIGER Study).Am J Cardiol,2013,112:1834-1839.
• [34]Sakao S,Tanabe N,Kasahara Y,et al.Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium,an oral prostacyclin analogue.Intern Med,2014,53:1913-1920.
• [35]GalièN,Beghetti M,Gatzoulis MA,et al.Bosentan therapy in patients with Eisenmenger syndrome:a multicenter,doubleblind,randomized,placebo-controlled study.Circulation,2006,114:48-54.
• [36]Berger RM,Beghetti M,GalièN,et al.Atrial septal defects versus ventricular septal defects in BREATHE-5,a placebocontrolled study of pulmonary arterial hypertension related to Eisenmenger's syndrome:a subgroup analysis.Int J Cardiol,2010,144:373-378.
• [37]Vis JC,Duffels MG,Mulder P,et al.Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.Int J Cardiol,2013,164:64-69.
• [38]Badesch DB,Feldman J,Keogh A,et al.ARIES-3:ambrisentan therapy in a diverse population of patients with pulmonary hypertension.Cardiovasc Ther,2012,30:93-99.
• [39]Zuckerman WA,Leaderer D,Rowan CA,et al.Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.Am J Cardiol,2011,107:1381-1385.
• [40]Mc Goon MD,Frost AE,Oudiz RJ,et al.Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.Chest,2009,135:122-129.
• [41]Condliffe R,Elliot CA,Hurdman J,et al.Ambrisentan therapy in pulmonary hypertension:clinical use and tolerability in a referral centre.Ther Adv Respir Dis,2014,8:71-77.
• [42]Patel T,Mc Keage K.Macitentan:first global approval.Drugs,2014,74:127-133.
• [43]张端珍,朱鲜阳,贾丽娟,等.西地那非治疗先天性心脏病相关性肺动脉高压的有效性与安全性.心脏杂志,2012,24:600-603.
• [44]夏燕亮,马如海,陈宏.西地那非治疗高原地区先天性心脏病合并重度肺动脉高压的疗效和安全性.中国循环杂志,2014,29:702-705.
• [45]GalièN,Ghofrani HA,Torbicki A,et al.Sildenafil citrate therapy for pulmonary arterial hypertension.N Engl J Med,2005,353:2148-2157.
• [46]Rubin LJ,Badesch DB,Fleming TR,et al.Long-term treatment with sildenafil citrate in pulmonary arterial hypertension:the SUPER-2 study.Chest,2011,140:1274-1283.
• [47]Maxey DM,Ivy DD,Ogawa MT,et al.Food and Drug Administration(FDA)postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.Pediatr Cardiol,2013,34:1628-1636.
• [48]Matamis D,Pampori S,Papathanasiou A,et al.Inhaled NO and sildenafil combination in cardiac surgery patients with out-ofproportion pulmonary hypertension:acute effects on postoperative gas exchange and hemodynamics.Circ Heart Fail,2012,5:47-53.
• [49]Arif SA,Poon H.Tadalafil:a long-acting phosphodiesterase-5inhibitor for the treatment of pulmonary arterial hypertension.Clin Ther,2011,33:993-1004.
• [50]Buckley MS,Staib RL,Wicks LM,et al.Phosphodiesterase-5inhibitors in management of pulmonary hypertension:safety,tolerability,and efficacy.Drug Healthc Patient Saf,2010,2:151-161.
• [51]Bharani A,Patel A,Saraf J,et al.Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.Indian Heart J,2007,59:323-328.
• [52]Mukhopadhyay S,Nathani S,Yusuf J,et al.Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized,placebo-controlled,double-blind crossover study.Congenit Heart Dis,2011,6:424-431.
• [53]Shiva A,Shiran M,Rafati M,et al.Oral tadalafil in children with pulmonary arterial hypertension.Drug Res(Stuttg),2015.[Epub ahead of print].
• [54]Ghofrani HA,GalièN,Grimminger F,et al.Riociguat for the treatment of pulmonary arterial hypertension.N Engl J Med,2013,369:330-340.
• [55]Conole D,Scott LJ.Riociguat:first global approval.Drugs,2013,73:1967-1975.
• [56]Simonneau G,Rubin LJ,GalièN,et al.Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.J Heart Lung Transplant,2014,33:689-697.
• [57]张曹进,黄奕高,黄涛,等.伊诺前列素联合小剂量他达那非治疗成人先天性心脏病并重度肺动脉高压的单中心、开放、对照研究.中华心血管病杂志,2014,42:474-480.
• [58]Yusen RD,Christie JD,Edwards LB,et al.The Registry of the International Society for Heart and Lung Transplantation:Thirtieth Adult Lung and Heart-Lung Transplant Report—2013;focus theme:age.J Heart Lung Transplant,2013,32:965-978.
• [59]Besterman E.Atrial septal defect with pulmonary hypertension.Br Heart J,1961,23:587-598.
• [60]Vogel M,Berger F,Kramer A,et al.Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects.Heart,1999,82:30-33.
• [61]Craig RJ,Selzer A.Natural history and prognosis of atrial septal defect.Circulation,1968,37,805-815.
• [62]Campbell M.Natural history of atrial septal defect.Br Heart J,1970,32:820-826.
• [63]Attie F,Rosas M,Granados N,et al.Surgical treatment for secundum atrial septal defects in patients>40 years old.A randomized clinical trial.J Am Coll Cardiol,2001,38:2035-2042.
• [64]O'Donnell C,Ruygrok PN,Whyte K,et al.Progressive pulmonary hypertension post atrial septal defect device closureearly symptomatic improvement may not predict outcome.Heart,Lung and Circulation,2010,19:713-716.
• [65]Sachweh JS,Daebritz SH,Hermanns B,et al.Hypertensive pulmonary vascular disease in adults with secundum or sinus venosus atrial septal defect.Ann Thorac Surg,2006,81:207-213.
• [66]GalièN,Hoeper MM,Humbert M,et al.Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur Respir J,2009,34:1219-1263.
• [67]Roberts KE,Mc Elroy JJ,Wong WP,et al.BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.Eur Respir J,2004,24:371-374.
• [68]Therrien J,Rambihar S,Newman B,et al.Eisenmenger syndrome and atrial septal defect:nature or nurture?Can J Cardiol,2006,22:1133-1136.
• [69]Sanchez-Recalde A,Oliver JM,Galeote G,et al.Atrial septal defect with severe pulmonary hypertension in elderly patients:usefulness of transient balloon occlusion.Rev Esp Cardiol,2010,63:860-864.
• [70]陈火元,朱鲜阳,韩秀敏,等.成人房间隔缺损合并肺动脉高压患者导管封堵术后左心功能变化.介入放射学杂志,2013,22:365-368.
• [71]Providência R,Botelho A,Quintal N,et al.Pulmonary hypertension in patients with ostium secundum atrial septal defect--is it related to echocardiographic complexity?Rev Port Cardiol,2009,28:1087-1096.
• [72]Engelfriet PM,Duffels MG,Moller T,et al.Pulmonary arterial hypertension in adults born with a heart septal defect:the Euro Heart Survey on adult congenital heart disease.Heart,2007,93:682-687.
• [73]Rosenzweig EB,Barst RJ.Congenital heart disease and pulmonary hypertension:pharmacology and feasibility of late surgery.Prog Cardiovasc Dis,2012,55:128-33.
• [74]Provencher S,Sitbon O,Humbert M,et al.Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.Eur Heart J,2006,27:589-595.
• [75]Serino G,Giacomazzi F,et al.Pulmonary arterial hypertension in adult patients with congenital heart disease.Pediatr Med Chir,2010,32:274-279.
• [76]Farber HW,Foreman AJ,Miller DP,et al.REVEAL Registry:correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension.Congest Heart Fail,2011,17:56-64.
• [77]Roos-Hesselink JW,Meijbboom FJ,Spitaels SE,et al.Outcome of patients after surgical closure of ventricular septal defect at young age:longitudinal follow-up of 22-34 years.Eur Heart J,2004,25:1057-1062.
• [78]Mendelof EN,Meyers BF,Sundt TM,et al.Lung transplantation for pulmonary vascular disease.Ann Thorac Surg,2002,73:209-2l7.
• [79]Yan C,Zhao S,Jiang S,et al.Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults.Heart,2007,93:514-518.
• [80]Zhang DZ,Zhu XY,Lv B,et al.Trial occlusion to assess the risk of persistent pulmonary arterial hypertension after closure of a large patent ductus arteriosus in adolescents and adults with elevated pulmonary artery pressure.Circ Cardiovasc Interv,2014,7:473-481.
• [81]Friedman WF.Proceedings of National Heart,Lung,and Blood Institute pediatric cardiology workshop:pulmonary hypertension.Pediatr Res,1986,20:811-824.
• [82]Beghetti M.Congenital heart disease and pulmonary hypertension.Rev Port Cardiol,2004,23:273-281.
• [83]Granton JT,Rabinovitch M.Pulmonary arterial hypertension in congenital heart disease.Cardiol Clin,2002,20:441-457.
• [84]Seghaye MC.The clinical implications of the systemic inflammatory reaction related to cardiac operations in children.Cardiol Young,2003,13:228-239.
• [85]Kageyama K,Hashimoto S,Nakajima Y,et al.The change of plasma endothelin-1 levels before and after surgery with or without Down syndrome.Paediatr Anaesth,2007,17:1071-1077.
• [86]Hopkins RA,Bull C,Haworth SG,et al.Pulmonary hypertensive crises following surgery for congenital heart defects in young children.Eur J Cardiothorac Surg,1991,5:628-634.
• [87]Atz AM,Lefler AK,Fairbrother DL,et al.Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises.J Thorac Cardiovasc Surg,2002,124:628-629.
• [88]Polderman FN,Cohen J,Blom NA,et al.Sudden unexpected death in children with a previously diagnosed cardiovascular disorder.Int J Cardiol,2004,95:171-176.
• [89]GalièN,Hoeper MM,Humbert M,et al.Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS),endorsed by the International Society of Heart and Lung Transplantation(ISHLT).Eur Heart J,2009,30:2493-2537.
• [90]Simonneau G,Barst RJ,Galie N,et al.Continuous subcutaneous infusion of treprostinil,a prostacyclin analogue,in patients with pulmonary arterial hypertension.a doubleblind,randomized,placebo-controlled trial.Am J Respir Crit Care Med,2002,165:800-804.
• [91]Rubin LJ,Badesch DB,Barst RJ,et al.Bosentan therapy for pulmonary arterial hypertension.N Engl J Med,2002,346:896-903.
• [92]Galie N,Humbert M,Vachiery JL,et al.Effects of beraprost sodium,an oral prostacyclin analogue,in patients with pulmonary arterial hypertension:a randomized,double-blind placebo-controlled trial.J Am Coll Cardiol,2002,39:1496-1502.
• [93]Barst RJ,Langleben D,Badesch D,et al.Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.J Am Coll Cardiol,2006,47:2049-2056.
• [94]Barst RJ,Langleben D,Frost A,et al.Sitaxsentan therapy for pulmonary arterial hypertension.Am J Respir Crit Care Med,2004,169:441-447.
• [95]Beghetti M,GalièN.Eisenmenger syndrome:a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.J Am Coll Cardiol,2009,53:733-740.
• [96]Bando K,Turrentine MW,Sharp TG,et al.Pulmonary hypertension after operations for congenital heart disease:analysis of risk factors and management.J Thorac Cardiovasc Surg,1996,112:1600-1607.
• [97]陈果,何建国,柳志红,等.不同类型肺动脉高压患者临床特征和血流动力学的比较分析.中国循环杂志,2013,28:300-303.
• [98]孙云娟,逢坤静,曾伟杰,等.先天性心脏病相关性肺动脉高压的临床筛查.中华医学杂志,2012,92:1091-1094.
• [99]Dimopoulos K,Inuzuka R,Goletto S,et al.Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension.Circulation,2010,121:20-25.
• [100]Manes A,Palazzini M,Leci E,et al.Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease:a comparison between clinical subgroups.Eur Heart J,2014,35:716-724.